Thursday, December 14, 2017
Home Authors Posts by Cell Tribune

Cell Tribune

42 POSTS 0 COMMENTS
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.

Cancer immune therapy developed from ‘miraculous’ recovery patients

A new immune therapy developed from “miraculous” cases of cancer recovery could be tested on human patients next year. The treatment uses cancer-killing immune...

Creative Biolabs Announced Bio-distribution Analysis Services for CAR-T Cell Therapy

Creative Biolabs, a frontier biotech service provider that offers high-quality antibody products, announced today their preclinical viability and bio-distribution analysis services for CAR-T cell...

Eutilex and Huahai Enter Immuno-Oncology Strategic Partnership Paving New Momentum into...

SEOUL, South Korea, Nov. 6, 2017 /PRNewswire/ -- Eutilex Co. Ltd. today announced that it has entered into a strategic partnership with China's fast-growing Zhejiang Huahai Pharmaceutical Ltd. --...

First systematic study of infections after CAR T-cell therapy

In the first systematic study of its kind, researchers at Fred Hutchinson Cancer Research Center report comprehensive data on infectious complications of an emerging cancer immunotherapy...

ViaCyte Awarded New CIRM Grant to Support Clinical Trial of PEC-Direct...

SAN DIEGO, Sept. 28, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced that the California Institute for Regenerative Medicine (CIRM) approved a grant...

ViaCyte Announces First Patients Implanted with PEC-Direct Islet Cell Replacement Therapy...

San Diego, August 1, 2017 — ViaCyte, Inc., a privately-held, leading regenerative medicine company, announced today that the first patients have been implanted with the...

Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows...

Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed...

Healing wounds with cell therapy

An experimental treatment in mice allows the reprogramming of blood cells in order to promote the healing process of cutaneous wounds. This approach could...

FDA Grants Breakthrough Therapy Designation to Novartis’s CAR-T Cell Therapy CTL019

The FDA granted a breakthrough therapy designation to Novartis’s CTL019, a chimeric antigen receptor T cell immunotherapy, or CAR-T, for the treatment of adult...

ViaCyte to Present at Four Upcoming Healthcare Events

SAN DIEGO, February 21, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced four presentations at upcoming healthcare events.  ViaCyte is advancing...